Sen. Sheldon Whitehouse Purchases Guardant Health, Inc. (NASDAQ:GH) Shares

Senator Sheldon Whitehouse (D-Rhode Island) recently bought shares of Guardant Health, Inc. (NASDAQ:GH). In a filing disclosed on December 01st, the Senator disclosed that they had bought between $1,001 and $15,000 in Guardant Health stock on November 21st.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of CocaCola (NYSE:KO) on 11/21/2025.
• Sold $15,001 – $50,000 in shares of Progressive (NYSE:PGR) on 10/27/2025.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 10/20/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 9/4/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of UnitedHealth Group (NYSE:UNH) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 9/4/2025.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 9/4/2025.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $105.96 on Thursday. The firm has a market capitalization of $13.36 billion, a P/E ratio of -33.01 and a beta of 1.58. The stock has a 50 day moving average price of $82.86 and a 200-day moving average price of $62.34. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. Guardant Health’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.88) earnings per share. On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity at Guardant Health

In other Guardant Health news, insider Terilyn J. Monroe sold 55,167 shares of Guardant Health stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $105.97, for a total value of $5,846,046.99. Following the completion of the sale, the insider owned 20,920 shares of the company’s stock, valued at approximately $2,216,892.40. The trade was a 72.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,500 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $95.19, for a total value of $142,785.00. Following the transaction, the director directly owned 815 shares in the company, valued at $77,579.85. The trade was a 64.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 368,228 shares of company stock valued at $24,835,525. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP increased its holdings in shares of Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock worth $53,000 after purchasing an additional 138 shares in the last quarter. TD Waterhouse Canada Inc. increased its holdings in Guardant Health by 3.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after buying an additional 151 shares in the last quarter. Signaturefd LLC raised its position in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after buying an additional 213 shares during the last quarter. American Century Companies Inc. lifted its stake in Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after acquiring an additional 282 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in Guardant Health by 8.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock valued at $251,000 after acquiring an additional 307 shares during the period. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Evercore ISI increased their price target on shares of Guardant Health from $68.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. UBS Group upped their price objective on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Canaccord Genuity Group set a $100.00 target price on shares of Guardant Health in a report on Thursday, October 30th. Leerink Partners boosted their price target on Guardant Health from $70.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $80.86.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031.

Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.